Main Article Content



  1. This is the first systematic review investigating thrombocytopenia and its association with retinopathy of prematurity.

  2. Thrombocytopenia can be a useful clinical biomarker in retinopathy of prematurity screening, considering the quick, affordable, and widespread availability of the examination.



Retinopathy of prematurity (ROP) is the primary cause of childhood blindness. It arises from the underdevelopment of retinal blood vessels in premature infants. Platelets have a vital function in the regulation of angiogenesis. Thus, thrombocytopenia may contribute to the progression of ROP. The objective of this systematic study was to examine the relationship between thrombocytopenia and ROP. The PubMed and Cochrane Library databases were accessed to search for retrospective, case-control, and cross-sectional studies. This study adhered to the guidelines outlined by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The literature search resulted in nine records to be analyzed in our review. All the selected studies were conducted between 2017 and 2022. Seven studies reported that the prevalence of thrombocytopenia in infants with ROP ranged from 18.37% to 71%. The frequency of thrombocytopenia in preterm children without ROP was between 5.71% and 21%. Thrombocytopenia was identified as a risk factor for ROP in seven studies, with the odds ratio (OR) for thrombocytopenia ranging from 2.8 to 6.69. Thrombocytopenia in premature infants can potentially serve as a clinical biomarker in the screening of type 1 ROP. This finding suggests that thrombocytopenia may contribute to the pathophysiology of ROP. Further research is necessary to determine the critical threshold platelet count for thrombocytopenia in infants with ROP.


Thrombocytopenia retinopathy of prematurity preterm infant angiogenesis childbirth complications

Article Details

How to Cite
Sutyawan, I. W. E., Surasmiati, N. M. A., Agrasidi, P. A., Dwianggita, P., & Anggara, S. A. (2023). Thrombocytopenia as a Clinical Biomarker of Retinopathy of Prematurity. Folia Medica Indonesiana, 59(4), 410–417.


  1. Cakir B, L.R.H.G.L.P.S.Y.K.S. et al (2018) ‘Thrombocytopenia is associated with severe retinopathy of prematurity’, JCI insight, 3(19).
  2. Choręziak A, S.D.C.-C.A.P.I.G.-W.A. (2022) ‘The association of platelet counts with development and treatment for retinopathy of prematurity - is thrombocytopenia a risk factor?’, Arch Med Sci, 18(2), pp. 400–5.
  3. Faheem, MA. (2021). ‘Effect of Platelet Transfusion on Retinopathy of Prematurity- Hospital based Prospective Study’, Annals of R.S.C.B. 25(6), pp. 5442-5448.
  4. Gaber, R. et al. (2021) ‘Incidence and Risk Factors for Retinopathy of Prematurity (ROP) in Biggest Neonatal Intensive Care Unit in Itay Elbaroud City, Behera Province, Egypt.’, Clinical ophthalmology (Auckland, N.Z.), 15, pp. 3467–3471. Available at:
  5. Gaber R, S.O.S.A.S.H. (2021) ‘ncidence and Risk Factors for Retinopathy of Prematurity (ROP) in Biggest Neonatal Intensive Care Unit in Itay Elbaroud City, Behera Province, Egypt’, Clin Ophthalmol, 15, pp. 3467–3471.
  6. Hellgren G., L.P., P.A., L.C., N.A.K., L.D., S.K., S.L.E., H.A. (2021) ‘Decreased Platelet Counts and Serum Levels of VEGF-A, PDGF-BB, and BDNF in Extremely Preterm Infants Developing Severe ROP’, Neonatology, 118, pp. 18–27.
  7. Hong EH, S.Y.C.H. (2022) ‘Retinopathy of prematurity: a review of epidemiology and current treatment strategies’, Clin Exp Pediatr, 65(3), pp. 115–26.
  8. Jensen AK, Y.G.H.J.Q.G.B.G. (2018) ‘Longitudinal study of the association between thrombocytopenia and retinopathy of prematurity’, J AAPOS Off Publ Am Assoc Pediatr Ophthalmol Strabismus, 22(2), pp. 119–23.
  9. Keşkek, NS., G.H., Y.G., A.I. (2020) ‘Impact of Platelet Count in Retinopathy of Prematurity’, Turk J Ophtalmol , 50(6).
  10. Lundgren P, L.L.H.G.H.G.H.A.S.L. et al (2017) ‘Aggressive Posterior Retinopathy of Prematurity Is Associated with Multiple Infectious Episodes and Thrombocytopenia’, Neonatology, 111(1), pp. 79–85.
  11. Margraf A, N.C.S.M. (2019) ‘Ontogeny of platelet function’, Blood Adv, 3(4), pp. 692–703.
  12. Özkaya D (2022) ‘The Role of Thrombocyte Parameters in Retinopathy of Prematurity Development’, Int J Clin Pract [Preprint].
  13. Parlak, M. and Tsokhla, R., M.B., S.A., W.A. (2020) ‘Thrombocytopenia in association with severe retinopathy of prematurity: a longitudinal study over 15 years’, Euretina [Preprint].
  14. Parrozzani R, N.E.B.S.M.G.S.S.N.D. et al (2021) ‘Severe retinopathy of prematurity is associated with early post-natal low platelet count’, Sci Rep, 11(1), p. 891.
  15. Resch E, H.O.U.B.R.B. (2018) ‘Neonatal thrombocytopenia-causes and outcomes following platelet transfusions’, Eur J Pediatr, 177(7), pp. 1045–52.
  16. Sancak S, T.H.G.Y.T.K.G.O.F. (2019) ‘Thrombocytopenia As A Risk Factor For Retinopathy Of Prematurity’, Retina, 39(4), pp. 706–11.
  17. Seliniotaki AK, H.A.M.S.L.M.Z.N.L.P. et al (2022) ‘Association of platelet deficiency with severe retinopathy of prematurity: a review’, Acta Paediatr [Preprint].
  18. Seliniotaki, A. (2022). ‘Is thrombocytopenia and postnatal weight gain associated with treatment‐requiring retinopathy of prematurity? A matched case–control study’, Acta Paediatr
  19. Wood EH et al. (2021) ‘80 Years of vision: preventing blindness from retinopathy of prematurity’, J Perinatol, 41(6), pp. 1216–24.
  20. Wu AL, W.WC. (2018) ‘Anti-VEGF for ROP and Pediatric Retinal Diseases. Asia-Pacific J Ophthalmol (Philadelphia, Pa)’, 7(3), pp. 145–51.
  21. Yau GSK, L.J.T.V.Y.S.C.E.L.C. et al (2015) ‘Incidence and risk factors for retinopathy of prematurity in multiple gestations: a Chinese population study’, Medicine (Baltimore), 94(18).